Start your Trading & Investing Journey with us

Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates

Amanta Healthcare IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details

Amanta Healthcare IPO Review

Amanta Healthcare is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal (“ABFS”) and Injection Strech Blow Moulding (“ISBM”) technology. They manufacture large volume parenterals (“LVPs”) and small volume parenterals (“SVPs”) in six therapeutic segments. In addition to that, they also manufacturer medical devices. 

The company is led by a qualified and experienced management team that the company believe has the experience and vision to manage and grow thw business. The Promoter, Chairman and Managing Director, Bhavesh Patel has approximately 30 years’ industry experience in the field of manufacturing and marketing of pharmaceutical products. In addition to the Promoters, the senior management team is also experienced in the pharmaceutical industry and possess a range of qualifications, including graduate and post-graduate degrees in Accounts, science and pharmacy.

The Revenues from operations for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 27,609.34 Lakh, ₹ 28,160.68 Lakh and ₹ 26,269.62 Lakh. The EBITDA for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were ₹ 13,569.13 Lakh, ₹ 12,313.42 Lakh and ₹ 10,731.76 Lakh. The Profit after Tax for the Fiscals ended on Mar 31, 2025, 2024 and 2023 were were ₹ 1,050.07 Lakh, ₹ 363.32 Lakh and ₹ -211.06 Lakh respectively. This indicates a steady growth in financial performance.

The Company Key Performance Indicates the pre-issue EPS of ₹ 3.71 and post-issue EPS of ₹ 2.70 for FY24. The pre-issue P/E ratio is 33.96x, while the post-issue P/E ratio is 46.59x against the Industry P/E ratio is 16x. The company's ROCE for FY24 is 13.72%, ROE for FY24 is 12.42% and RoNW is 10.89%. These metrics suggest that the IPO is fully priced.

The Grey Market Premium (GMP) of Amanta Healthcare showing listing gains of 11.11 %.Given the company's financial performance and the valuation of the IPO, we recommend Risky Investors to Apply to the Amanta Healthcare Limited IPO for Listing gain.


Disclaimer: The information provided in this IPO review is for educational and informational purposes only and should not be construed as financial advice or an offer to buy or sell securities. The review must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. The content is based on publicly available information and market perceptions as of the date of publication and is subject to change. Neither the author nor the website is responsible for any losses or damages arising from the use of this information. 1.“Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.” 2. “Investment in securities market are subject to market risks. Read all the related documents carefully before investing.” 3. To read the Disclaimers, Disclosures, Investor Charter, Investor Complaints please visit our website abhayvarn.com

About the Author
CA Abhay Kumar (Also known as  CA Abhay Varn) is a qualified Chartered Accountant by profession and cleared CA at age 21. He is a SEBI Registered Research Analyst with Registration Number - INH300008465. He Possesses 8+ years of experience in the Stock Market Field and has also worked in Big CA firms.

© 2022 CA Abhay Varn. All Rights Reserved Abhayvarn.com